Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "H-Clinical"

80 News Found

H Clinical adds commercial home health capabilities for pharma industry
News | July 01, 2022

H Clinical adds commercial home health capabilities for pharma industry

H Clinical is the leader in decentralized clinical trial support and home visits in Latin America


Biocon Foundation and IISc commemorate World Head & Neck Cancer Day
News | July 29, 2025

Biocon Foundation and IISc commemorate World Head & Neck Cancer Day

This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines


Zambon launches intravenous formulation of Fluimucil
Drug Approval | June 29, 2025

Zambon launches intravenous formulation of Fluimucil

The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile


Sai Life Sciences commences commercial operation of 2nd phase in Bidar
News | June 23, 2025

Sai Life Sciences commences commercial operation of 2nd phase in Bidar

This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility


Fortis Healthcare launches Fortis Institute of Genomic Medicine
News | April 17, 2025

Fortis Healthcare launches Fortis Institute of Genomic Medicine

Genomics is transforming the future of modern medicine and treatment modalities across specialties


Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
News | March 20, 2025

Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions

The new site will increase Syngene's total single-use bioreactor capacity to 50,000L


Syngene acquires first US biologics facility for $36.5 million
News | March 11, 2025

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million


Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody
Diagnostic Center | December 10, 2024

Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody

Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma